[
  {
    "ts": null,
    "headline": "Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference",
    "summary": "TARRYTOWN, N.Y., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025. The presentation is scheduled for 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time) and may be accessed from the \"Investors & Media\" page of Regeneron's website at http://investor.regeneron.com/events-and-presentations.com/events-and-presentations. A replay and transcript of the webcast will",
    "url": "https://finnhub.io/api/news?id=5ae50934f39587f3611bdd0564ff26f3fdd8b8a3160f2cb2f74611da0a95f26e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734469500,
      "headline": "Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference",
      "id": 132036602,
      "image": "https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "TARRYTOWN, N.Y., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025. The presentation is scheduled for 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time) and may be accessed from the \"Investors & Media\" page of Regeneron's website at http://investor.regeneron.com/events-and-presentations.com/events-and-presentations. A replay and transcript of the webcast will",
      "url": "https://finnhub.io/api/news?id=5ae50934f39587f3611bdd0564ff26f3fdd8b8a3160f2cb2f74611da0a95f26e"
    }
  },
  {
    "ts": null,
    "headline": "Bayer’s Eye Drug Shows Positive Results in Late-Stage Trial",
    "summary": "Bayer said its eye treatment aflibercept showed positive results in a late-stage trial, including improved vision gains for people suffering from some retinal diseases.",
    "url": "https://finnhub.io/api/news?id=b1c6257f423d256135ed1374f6498274df9f45694cfefd8235713d2b9a1bf134",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734442440,
      "headline": "Bayer’s Eye Drug Shows Positive Results in Late-Stage Trial",
      "id": 132036603,
      "image": "",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Bayer said its eye treatment aflibercept showed positive results in a late-stage trial, including improved vision gains for people suffering from some retinal diseases.",
      "url": "https://finnhub.io/api/news?id=b1c6257f423d256135ed1374f6498274df9f45694cfefd8235713d2b9a1bf134"
    }
  },
  {
    "ts": null,
    "headline": "EYLEA HD® (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion",
    "summary": "EYLEA HD demonstrated non-inferior vision gains with an every 8-week dosing regimen compared to EYLEA® (aflibercept) Injection 2 mg dosed every 4 weeks Safety data remains consistent with the known EYLEA HD and EYLEA safety profiles Supplementary biologics license application planned for submission to the U.S. Food and Drug Administration in the first quarter of 2025 TARRYTOWN, N.Y., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the primary endp",
    "url": "https://finnhub.io/api/news?id=0dabd65c71fb210c8675140e380345c36d79e72a892e83064fda3a43433ff506",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734436800,
      "headline": "EYLEA HD® (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion",
      "id": 132027343,
      "image": "",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "EYLEA HD demonstrated non-inferior vision gains with an every 8-week dosing regimen compared to EYLEA® (aflibercept) Injection 2 mg dosed every 4 weeks Safety data remains consistent with the known EYLEA HD and EYLEA safety profiles Supplementary biologics license application planned for submission to the U.S. Food and Drug Administration in the first quarter of 2025 TARRYTOWN, N.Y., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the primary endp",
      "url": "https://finnhub.io/api/news?id=0dabd65c71fb210c8675140e380345c36d79e72a892e83064fda3a43433ff506"
    }
  },
  {
    "ts": null,
    "headline": "Is Regeneron Pharmaceuticals, Inc. (REGN) the Best Weight Loss Stock to Buy Now According to Hedge Funds?",
    "summary": "We recently compiled a list of the 12 Best Weight Loss Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other weight loss stocks. The Revolution in Obesity Treatment: Opportunities and Challenges of GLP-1 Medications Most people have at […]",
    "url": "https://finnhub.io/api/news?id=06e92d70c6714d6711a4d9618249b77ad6e6f07e903a8fabc5ccb0acb010ce8d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734436408,
      "headline": "Is Regeneron Pharmaceuticals, Inc. (REGN) the Best Weight Loss Stock to Buy Now According to Hedge Funds?",
      "id": 132027344,
      "image": "https://s.yimg.com/ny/api/res/1.2/jMekiCT4mZ2_S7szsjNT5A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/9b67531d4ce9e2fbb21fef60675f48d3",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 12 Best Weight Loss Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other weight loss stocks. The Revolution in Obesity Treatment: Opportunities and Challenges of GLP-1 Medications Most people have at […]",
      "url": "https://finnhub.io/api/news?id=06e92d70c6714d6711a4d9618249b77ad6e6f07e903a8fabc5ccb0acb010ce8d"
    }
  }
]